Jazz Pharmaceuticals

Jazz Pharmaceuticals PLC

Type	Private
Traded as	NASDAQ: JAZZ
Industry	Biotechnology
Headquarters	Dublin, Ireland
Key people	Bruce C. Cozadd (Chairman and CEO) Kathryn E. Falberg (CFO and Executive Vice President) Suzanne Sawochka Hooper (Executive Vice President and General Counsel) Russell J. Cox (Chief Commercial Officer) and Executive Vice President)
Products	Xyrem, FazaClo, FazaClo HD, Luvox CR, Prialt
Revenue	$340.9 million Q3 2015[1]
Net income	$159.3 million Q3 2015[1]
Website	www.jazzpharma.com

Jazz Pharmaceuticals PLC (a merger of Jazz Pharmaceuticals and Azur Pharma PLC) is a biopharmaceutical company which specializes of identifying, developing and commercializing pharmaceutical products. One of the company's most significant products is the United States Food and Drug Administration (FDA) approved drug, Xyrem (Sodium Oxybate - another term for the identical substance more commonly referred to as GHB Gamma Hydroxy Butrate).

Company history & Acquisitions

2010

On February 18, the FDA accepted a new drug application for JZP-6 (Sodium Oxybate) for the treatment of Fibromyalgia^[2] In the following December, a new patent was issued for Sodium Oxybate ^[3]

2011

On September 19, Jazz Pharmaceuticals and Azur Pharma PLC agreed to merge^[4]

2012

On April 26, the company acquired EUSA Pharma for $650 million (plus $50 million in milestone payments^[5] In September the company successfully sold its Women's Health business to Meda for $95 million ^[6] In December, the company began clinical trial of intravenous Erwinaze in patients suffering from Acute Lymphoblastic Leukemia ^[7]

2014

In January, the company announced it would acquire the rare disease drug developer Gentium SpA and its lead product Defitelio for US$1 billion^[8][9]

Acquisition history

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Jazz Pharmaceuticals	(Merged 2011) Jazz Pharmaceuticals Azur Pharma PLC EUSA Pharma (Acq 2012) Gentium SpA (Acq 2014)

Products

• Xyrem – used for excessive daytime sleepiness and cataplexy in narcoleptics.
• FazaClo (and FazaClo HD) – used in the management of patients severely ill with schizophrenia.
• Luvox CR – used in the treatment of patients with Obsessive compulsive disorder
• Parcopa

References

1. Jazz Pharmaceuticals (9 November 2015). "Jazz Pharmaceuticals Announces Third Quarter 2015 Financial Results". prnewswire.com.
2. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
3. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
4. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
5. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
6. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
7. "Jazz Pharmaceuticals - Investor & Media - Press Release". jazzpharma.com.
8. Armstrong, Drew (December 19, 2013). "Jazz to Buy Gentium for $1 Billion for Rare-Disease Drugs". Bloomberg News.
9. "Jazz Pharma Acquiring Gentium for $1B". Gen. Eng. Biotechnol. News (paper) 34 (2). January 15, 2014. p. 10.